Merck up as viral infection drug meets main goal in late-stage study

Panacea Biotec

24/10/2022 16:22

** Shares of Merck & Co Inc  MRK.N  rise 2% to $97.6 
    ** Co said on Saturday its drug candidate to treat viral
infection called Cytomegalovirus (CMV) in adults after kidney
transplantation meet primary goal in late-stage study
 urn:newsml:reuters.com:*:nBw90qjRKa
    ** The drug, Prevymis, when compared to already existing
generic drug, valganciclovir sold by Cipla  CIPL.NS , Zydus
Cadila, Panacea Biotec Ltd  PNCA.NS  was effective and
non-inferior in preventing viral infection
    ** European Commission also expand MRK's pneumonia vaccine,
Vaxneuvance, to include infants, children and adolescents from 6
weeks to less than 18 years of age  urn:newsml:reuters.com:*:nBw1dmrbba
    ** Including session's gain, stock is up ~27% YTD
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))